BrightSpring Health price target raised to $30 from $22 at UBS

UBS raised the firm’s price target on BrightSpring Health (BTSG) to $30 from $22 and keeps a Buy rating on the shares. BrightSpring has seen more than 25% growth in oncology with no signs of slowing due to the $90B of new drugs expected to come to the market over the next 7-9 years, which will create a continual flow of innovative new brands coming to the market where the company is winning the right to dispense 10-15 of these each year, the analyst tells investors in a research note.